Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings Of The Fortnight: Top-Ups The Latest Trend In Biopharmaceutical Deals

This article was originally published in The Pink Sheet Daily

Executive Summary

China Nuokang Bio-Pharmaceutical, Dendreon, Afferent Pharmaceuticals, and Molecular Partners end the year with new funds.

You may also be interested in...

Janssen Biotech Signs Option Agreement With Molecular Partners On Use Of DARPins In Immunological Diseases

Switzerland's Molecular Partners extends collaboration with Janssen on novel proteins, DARPins, in immune indications.

Newly NASDAQ-listed China Nuokang Sees Revenue Growth Spurt

HONG KONG - Underscoring the potential for growth for small biopharmaceutical companies, a Chinese developer and manufacturer of hematological and cardiovascular products reported higher earnings for 2009 and expects growth to carry into 2010

Ironwood Swings For The IPO Fences

The developer of a Phase III constipation drug wants to raise nearly $270 million in the first week of February. Will it hit a financing home run or strike out?

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts